National Academies Press: OpenBook
« Previous: References
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

A

Workshop Agenda

Deriving Drug Discovery Value from Large-Scale Genetic Bioresources:
A Workshop
March 22, 2016

The Keck Center of the National Academies of Sciences, Engineering, and Medicine, Room 100
500 Fifth Street, NW
Washington, DC 20001

MEETING OBJECTIVES

  • To address how progress can be made in discovering and validating promising targets and medicines for those targets by using data collected from large-scale genetic studies.
  • To highlight current genomics-enabled drug discovery activities in industry, academia, and government and to share best practices for study design and data collection.
  • To examine enabling partnerships and business models to facilitate the use of genetic data for drug discovery.

AGENDA

8:30–8:35 a.m. Welcoming Remarks

Geoffrey Ginsburg, Co-Chair of the Roundtable on Genomics and Precision Health

Director, Duke Center for Applied Genomics and Precision Medicine; Professor of Medicine and of Pathology and Biomedical Engineering, Duke University Medical Center

Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

Russ B. Altman, Co-Chair of the Forum on Drug Discovery, Development, and Translation

Professor of Bioengineering, Genetics, Medicine, and (by courtesy) Computer Science, Stanford University

8:35–8:45 a.m. Charge to Workshop Speakers and Participants

Nadeem Sarwar, Workshop Chair

President, Andover Product Creation Innovation Systems, Eisai Inc.

SESSION I: DESIGNING COHORTS TO MAXIMIZE DISCOVERY CAPABILITIES

Objectives: To explore current gaps and opportunities in data collected in large cohort studies and what elements could enable a robust discovery toolbox.

Moderator: Geoff Ginsburg, Co-Chair of the Roundtable on Genomics and Precision Health; Director, Duke Center for Applied Genomics and Precision Medicine

8:45–9:30 a.m. Joe Vockley

Chief Operating Officer and Chief Scientific Officer, Senior Vice President, Inova Translational Medicine Institute

Mark Daly

Co-Director, Program in Medical and Population Genetics, Broad Institute of the Massachusetts Institute of Technology and Harvard University

Aris Baras

Vice President, Co-Head, Regeneron Genetics Center, Regeneron Pharmaceuticals

Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
9:30–9:45 a.m. Break
Kári Stefánsson

Chairman, Chief Executive Officer, and Founder, deCODE genetics

Richard Scheller

Chief Science Officer, 23andMe

10:15–10:45 a.m. Discussion with Speakers and Attendees

SESSION II: CURRENT GENOME-ENABLED DISCOVERY ACTIVITIES RELATED TO BIORESOURCES

Objectives: To discuss current activities among stakeholder groups and innovative technologies, to identify gaps, and to explore opportunities for cross-sector engagement.

Moderator: John Carulli, Director, Precision Medicine, Biogen

10:45 a.m.–12:00 p.m. Russ Altman

Professor of Bioengineering, Genetics, and Medicine, Stanford University

Lon Cardon

Senior Vice President of Alternative Discovery and Development, Head of Target Sciences, GlaxoSmithKline

Sohini Chowdhury

Senior Vice President, Research Partnerships, The Michael J. Fox Foundation

Sally John

Vice President, Computational Biology and Genomics, Biogen Idec

Tim Rolph

Vice-President, Program Value Enhancement, Pfizer Inc.

Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
12:00–12:45 p.m. Discussion with Speakers and Attendees
12:45–1:45 p.m. WORKING LUNCH

SESSION III: BUSINESS MODELS THAT SUPPORT BIORESOURCE DISCOVERY COLLABORATION

Objectives: To examine potential precompetitive business models and investments that can support discovery efforts and opportunities across stakeholder groups.

Moderator: Rajesh Ranganathan, former Vice President of Science and Regulatory Advocacy, PhRMA

1:45–2:45 p.m. Lynn Matrisian

Vice President, Scientific & Medical Affairs, Pancreatic Cancer Action Network

Meg Ehm

Director, External Strategic Alliances, Genetics, GlaxoSmithKline

David Wholley

Accelerating Medicines Partnership and Foundation for the National Institutes of Health; Director, Research Partnerships, Foundation for the National Institutes of Health

Chas Bountra

Professor of Translational Medicine, Head of Structural Genomics Consortium, University of Oxford

2:45–3:30 p.m. Discussion with Speakers and Attendees
3:30–3:45 p.m. BREAK
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

SESSION IV: WHERE DO WE GO FROM HERE?

Objectives: What are the short-term and long-term next steps for achieving effective collaboration among stakeholders? Are there incentives that should be explored? How can we maximize use of large-scale genetic bioresources to effectively translate research into drug discovery?

Moderator: Nadeem Sarwar, Workshop Chair; President, Andover Product Creation Innovation Systems, Eisai Inc.

3:45–3:55 p.m. Dan Tagle

Associate Director for Special Initiatives, Office of the Director, National Center for Advancing Translational Sciences, National Institutes of Health

3:55–4:25 p.m. Panel Discussion
Russ Altman
Chas Bountra
Lon Cardon
Mark Daly
Richard Scheller
4:25–5:10 p.m. Discussion with Speakers and Attendees
5:10–5:25 p.m. SESSION HIGHLIGHTS
John Carulli
Geoff Ginsburg
Rajesh Ranganathan
5:25–5:30 p.m. CONCLUDING REMARKS
Nadeem Sarwar, Workshop Chair

President, Andover Product Creation Innovation Systems, Eisai Inc.

5:30 p.m. ADJOURN
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×

This page intentionally left blank.

Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 65
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 66
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 67
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 68
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 69
Suggested Citation:"Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2016. Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/23601.
×
Page 70
Next: Appendix B: Speaker Biographical Sketches »
Deriving Drug Discovery Value from Large-Scale Genetic Bioresources: Proceedings of a Workshop Get This Book
×
Buy Paperback | $45.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than $2 billion and takes 10 years to reach patients. The challenges associated with bringing new medicines to market have led many pharmaceutical companies to seek out innovative methods for streamlining their drug discovery research.

One way to increase the odds of success for compounds in the drug development pipeline is to adopt genetically guided strategies for drug discovery, and recognizing the potential benefits of collecting genetic and phenotypic information across specific populations, pharmaceutical companies have started collaborating with healthcare systems and private companies that have curated genetic bioresources, or large databases of genomic information. Large-scale cohort studies offer an effective way to collect and store information that can be used to assess gene–environment interactions, identify new potential drug targets, understand the role of certain genetic variants in the drug response, and further elucidate the underlying mechanisms of disease onset and progression.

To examine how genetic bioresources could be used to improve drug discovery and target validation, the National Academies of Sciences, Engineering, and Medicine hosted a workshop in March 2016. Participants at the workshop explored the current landscape of genomics-enabled drug discovery activities in industry, academia, and government; examined enabling partnerships and business models; and considered gaps and best practices for collecting population data for the purpose of improving the drug discovery process. This publication summarizes the presentations and discussions from the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!